New hope for tough breast cancer: drug plus radiation trial shows promise
NCT ID NCT03109080
First seen Jan 05, 2026 · Last updated May 24, 2026 · Updated 27 times
Summary
This early-phase trial tested the safety of combining the drug olaparib with radiation therapy in 24 women with advanced triple-negative breast cancer. The main goal was to find the highest safe dose of olaparib when given with radiation. The study focused on patients whose cancer had not responded to standard chemotherapy or had come back after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIOTHERAPY SIDE EFFECT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Curie
Paris, 75005, France
Conditions
Explore the condition pages connected to this study.